Fig. 1. Prevalence of SARS-CoV-2 antibodies in France.
a Estimated relative risks of seroprevalence by collection period, sex, age and region. Dots represent mean relative risk and bars 95% uncertainty interval of relative risk estimate over 104 iterations. Reference categories are indicated by a square. Collection periods are indicated by last day of each week (9–15 March 2020, 6–12 April 2020 and 11–17 May 2020). Regions: GUA Guadeloupe, MAR Martinique, GUY French Guiana, RUN La Réunion, IDF Île-de-France, CVL Centre-Val-de-Loire, BFC Bourgogne-Franche Comté, NOR Normandie, HDF Hauts-de-France, GES Grand-Est, PDL Pays de la Loire, BRE Bretagne, NAQ Nouvelle-Aquitaine, OCC Occitanie, ARA Auvergne-Rhône-Alpes, PAC Provence-Alpes-Côtes d’Azur, COR Corse. b Prevalence of SARS-CoV-2 antibodies in the French population by age group and collection period. Symbols represent mean estimate and bars 95% uncertainty interval of prevalence estimate over 104 iterations. c Prevalence of SARS-CoV-2 antibodies in the French population by region.
